Abstract:Background Eukaryotic initiation factor eIF4E, an important regulator of translation, plays a crucial role in the malignant transformation, progression and chemoresistance of many human solid tumors. The overexpression of this gene has been found in a variety of human malignancies including breast carcinoma. In the present study, we attempted to explore the possibility of eIF4E as a therapeutic target for the treatment of human breast carcinoma using breast carcinoma cell line (MCF-7). Materials and methods The survivin promoter-driven eIF4E-shRNA vector was constructed on the basis of pSUPER.retro vector. Then, we established stably transfected MCF-7 and MCF210 (normal human mammary epithelial cell) cells expressing eIF4E-shRNAs or control-shRNAs. Firstly, the changes of eIF4E expression were detected by RT-PCR and Western blot assays. Next, the optimal shRNA vector (eIF4E-shRNA2) was selected to knock down eIF4E expression and investigate the effect of eIF4E-shRNA on eIF4E-regulated gene expression and cell proliferation both in vitro and in vivo. Followingly, the changes of cell cycle and apoptosis in the stably transfectants (MCF-7) were detected by flow cytometry and TUNEL methods, while we also explored possible apoptosis pathways. Finally, we investigated the effect of shRNA targeting eIF4E on the chemosensitivity of breast carcinoma cells to cisplatin in vitro and in vivo. Results Two survivin promoter-driven eIF4E-shRNA vectors were successfully constructed. eIF4E-shRNA2 but not eIF4E-shRNA1 efficiently downregulated the levels of eIF4E expression in the stably transfected MCF-7-s2 cells but not in the stably transfected MCF210-s2 cells, while MCF-7-s2 showed obvious proliferation suppression but MCF210-s2 did not. The downregulation of eIF4E expression significantly reduced the levels of VEGF, FGF-2 and cyclinD1 expression, suppressed cell growth, induced cell cycle arrest in G0/G1 phase and subsequent apoptosis by activating caspase 3 in MCF-7 cells. The results of FCM and TUNEL staining assays indicated that the classic apoptosis characters of the MCF-7 cells stably expressing eIF4E-shRNA2 manifested an apoptosis rate of 18.3%, significantly higher than those in the control groups (P < 0.05). Morever, we found that downregulation of c-IAP1, c-IAP2 and c-Myc but not Bcl-2 family proteins were involved in the apoptosis induced by eIF4E-shRNA2. In tumorigenicity assay, xenograft tumors developed from MCF-7-s2 cells in mice showed a significant slowdown in the growth speed and formation rate compared with control groups. Furthermore, we also testified that eIF4E-shRNA could synergistically enhance the cytotoxicity effects of cisplatin to MCF-7 cells both in vitro and in vivo. Conclusion Survivin promoter–driven RNA interference system could efficiently and specifically downregulate eIF4E expression in human breast carcinoma cells but not in normal human mammary epithelial cell cells. Thus, eIF4E might play an important role in chemosensitivity to cisplatin, and survivin promoter-driven RNAi targeting eIF4E can be used as adjuvant therapy for human breast carcinomas with tumor specificity and high efficacy.

Gene Therapy with RNAi Targeting UHRF1 Driven by Tumor-Specific Promoter Inhibits Tumor Growth and Enhances the Sensitivity of Chemotherapeutic Drug in Breast Cancer in Vitro and in Vivo

RNAi-mediated downregulation of UHRF1 results in decreased human breast cancer cell growth

Inhibition effect of siRNA-downregulated UHRF1 on breast cancer growth.

Tumor-Targeting Nanocomplex Delivery Of Novel Tumor Suppressor Rb94 Chemosensitizes Bladder Carcinoma Cells In Vitro And In Vivo

The therapeutic potential of survivin promoter-driven siRNA on suppressing tumor growth and enhancing radiosensitivity of human cervical carcinoma cells via downregulating hTERT gene expression.

Tumor-specific RNAi Targeting Eif4e Suppresses Tumor Growth, Induces Apoptosis and Enhances Cisplatin Cytotoxicity in Human Breast Carcinoma Cells

Inhibition of Bcl-2 Expression by a Novel Tumor-Specific RNA Interference System Increases Chemosensitivity to 5-Fluorouracil in Hela Cells

Abstract 1235: Targeting RNA-binding Protein HuR to Inhibit Human Breast Cancer Invasion and Metastasis

Exogenous expression of UHRF1 promotes proliferation and metastasis of breast cancer cells.

Impact on U251 Cell Xenograft in vivo through Short Hairpin RNA Targeting Survivin Gene

Tumor-targeted Efficiency of Shrna Vector Harboring Chimera Htert/u6 Promoter.

Effect of UHRF1 gene inhibition on biological behavior of hepatoma cell

Adenoviral-Mediated Rna Interference Targeting Urg11 Inhibits Growth Of Human Hepatocellular Carcinoma

Survivin Stable Knockdown by Sirna Inhibits Tumor Cell Growth and Angiogenesis in Breast and Cervical Cancers

Suppression of Human MDA-MB-435S Tumor by U6 Promoter-Driven Short Hairpin RNAs Targeting Focal Adhesion Kinase

Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis

[Experimental Study on Bladder Cancer by the Small Interfering RNA Targeting Survivin].

Targeting the interaction between RNA-binding protein HuR and FOXQ1 suppresses breast cancer invasion and metastasis

Synthetic Tet-inducible Small Hairpin RNAs Targeting Htert or Bcl-2 Inhibit Malignant Phenotypes of Bladder Cancer T24 and 5637 Cells

Short Hairpin Rna Targeting Survivin Inhibits Growth And Angiogenesis Of Glioma U251 Cells

[Inhibition of Growth and Angiogenesis of U251 Cell Xenograft in Vivo by Short Hairpin RNA Targeting Survivin Gene].